Castleark Management’s Veracyte VCYT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$4.23M Buy
+72,016
New +$3.02M 0.11% 173
2025
Q2
Sell
-195,010
Closed -$5.78M 338
2025
Q1
$5.78M Buy
195,010
+25,580
+15% +$975K 0.2% 100
2024
Q4
$6.71M Sell
169,430
-7,130
-4% -$270K 0.23% 96
2024
Q3
$6.01M Buy
+176,560
New +$4.97M 0.25% 102
2024
Q1
Sell
-178,210
Closed -$4.9M 314
2023
Q4
$4.9M Buy
178,210
+51,120
+40% +$1.23M 0.22% 113
2023
Q3
$2.84M Sell
127,090
-1,370
-1% -$35.2K 0.14% 145
2023
Q2
$3.27M Buy
128,460
+17,560
+16% +$426K 0.15% 145
2023
Q1
$2.47M Buy
110,900
+80,130
+260% +$1.94M 0.12% 153
2022
Q4
$730K Buy
+30,770
New +$715K 0.04% 211
2021
Q4
Sell
-93,250
Closed -$4.33M 366
2021
Q3
$4.33M Buy
+93,250
New +$4.07M 0.17% 140
2021
Q2
Sell
-208,257
Closed -$11.2M 360
2021
Q1
$11.2M Sell
208,257
-43,575
-17% -$2.51M 0.4% 70
2020
Q4
$12.3M Buy
+251,832
New +$11.7M 0.46% 44
2019
Q4
Sell
-359,722
Closed -$8.63M 394
2019
Q3
$8.63M Sell
359,722
-46,330
-11% -$1.23M 0.35% 102
2019
Q2
$11.6M Buy
406,052
+167,687
+70% +$4.19M 0.44% 70
2019
Q1
$5.96M Buy
+238,365
New +$4.55M 0.22% 146

Other funds holding VCYT

Castleark Management's VCYT Position: Q2 2026 in Review

Castleark Management opened a new position in Veracyte (VCYT) in Q2 2026: 72,016 shares worth $4.23M. The stake represents 0.11% of the portfolio and ranks #173 among its holdings. This is a return to the name: Castleark Management previously reported a position in VCYT as recently as Q1 2025.

Castleark Management first reported a position in VCYT in Q1 2019 and has held it in 15 quarters since. The position peaked at $12.3M in Q4 2020. 370 funds tracked by Wall St. Rank hold VCYT as of Q2 2026.

  • Castleark Management held 72,016 shares of Veracyte worth $4.23M as of Q2 2026.
  • Veracyte was a new Castleark Management position in Q2 2026.
  • Veracyte made up 0.11% of Castleark Management's portfolio in Q2 2026, its #173 holding.
  • Castleark Management first reported a position in Veracyte in Q1 2019 and has held it in 15 quarters since.
  • Castleark Management's Veracyte position peaked at $12.3M in Q4 2020.
  • 370 funds tracked by Wall St. Rank held Veracyte as of Q2 2026.

Based on Castleark Management's 13F filing for Q2 2026, filed 14 Aug 2026.